Galmed Pharmaceuticals Valuation
Is GLMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GLMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GLMD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GLMD's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GLMD?
Other financial metrics that can be useful for relative valuation.
| What is GLMD's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$4.88m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does GLMD's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
SILO Silo Pharma | 0.8x | n/a | US$4.7m |
RUBY Rubius Therapeutics | 0.3x | n/a | US$5.2m |
AQB AquaBounty Technologies | 0.04x | 89.8% | US$4.6m |
FRES Fresh2 Group | 0.3x | n/a | US$4.5m |
GLMD Galmed Pharmaceuticals | 0.4x | n/a | US$4.9m |
Price-To-Book vs Peers: GLMD is expensive based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.4x).
Price to Earnings Ratio vs Industry
How does GLMD's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: GLMD is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.8x).
Price to Book Ratio vs Fair Ratio
What is GLMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate GLMD's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.